
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses adverse effects associated with asthma and COPD treatments.
Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses adverse effects associated with asthma and COPD treatments.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.






